Antagonist screening assay for CD27/CD70 axis

InvivoGen offers a cellular assay specifically designed for screening antibody-, Fc-fusion protein-, or small-molecule antagonists of the CD27/CD70 immune checkpoint (IC) axis. This assay is comprised of:

Principle of CD27/CD70 cellular assay
(click to enlarge)

InvivoGen also offers:

• Agonist screening assay for CD27/CD70 axis
• Fc-hCD70 fusion protein
• hCD27-Fc fusion protein

Jurkat-Lucia™ hCD27: Reporter T cells
Raji-Null: Antigen-presenting cells (APCs)

These paired cell lines allow the mimicking of the CD27-CD70-mediated co-stimulation between T cells and APCs.

CD27 is an immunostimulatory IC and a member of the TNFR (tumor necrosis factor receptor) superfamily. In humans, CD27 is constitutively expressed on most T cells, memory B cells, plasma cells, and Natural Killer cells. Expression of CD70 is tightly controlled and induced transiently in APCs following stimuli exposure, such as TFN-α, irradiation, or TLR agonists [1, 2]. The CD27–CD70 axis pair plays an important role in immune regulation. In concert with the T cell receptor (TCR) crosslinking, it contributes to efficient T cell activation, proliferation, survival, maturation of effector capacity, and T cell memory [1, 2].

More details

Note: If you are interested in a model that allows the mimicking of an immune synapse through T cell receptor (TCR) crosslinking with [HLA::peptide] complexes, along with the CD27-CD70 costimulatory interaction, please contact us.

Assay principle:

This assay relies on the co-culture of Jurkat-Lucia™ hCD27 and Raji-Null cells:
– Jurkat-Lucia™ hCD27 cells stably express cell surface CD27, along with an NF-κB-inducible Lucia luciferase reporter gene.
– Raji-Null cells express the CD70 activating IC ligand.
In the presence of a potent CD27 or CD70 antagonist, the CD27-CD70-mediated activation is blocked and there is no Lucia production. Activation of the reporter T cells can be readily measured using QUANTI-Luc™ 4 Lucia/Gaussia detection reagent (see Figures).

T-cell key features:

Stable human CD27 surface expression
Fully functional CD27 signaling pathway
NF-κB-inducible Lucia luciferase reporter activity

APC key features:

High surface expression of human CD70

InvivoGen also offers Jurkat-Lucia™ hCD27 cells without Raji-Null cells to measure the potency of agonists of the CD27/CD70 axis.

Read our review on Immune Checkpoint Blockade

Learn more about Immune Checkpoint Antibodies.

References:

1. Jacobs, J. et al. 2015. CD70: An emerging target in cancer immunotherapy. Pharmacol Ther 155, 1-10.
2. Buchan S.L, et al. 2018. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. Blood 131(1):39-48.

Clear allRefined by

Products6

Research Fields1

7 Search results: raji-apc-null